Phaseline

Companies › Verastem

Verastem: clinical trials, targets and expected readouts

3 active drug programs in 42 registered trials: 25 Phase 2, 15 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
avutometinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation …Dec 2026
defactinib
Focal adhesion kinase 1 inhibitor; Protein tyrosine kinase 2 beta inhibitor
PTK2, PTK2BPhase 3Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation …Dec 2026
VS-7375
KRAS G12D inhibitor
KRASPhase 2Colorectal Cancer; Non-Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Ductal AdenocarcinomaJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03875820avutometinibPhase 1NSCLCOncologyApr 2023
NCT03875820defactinibPhase 1NSCLCOncologyApr 2023
NCT04625270avutometinibPhase 2Low Grade Ovarian Serous AdenocarcinomaOncologyDec 2026
NCT04625270defactinibPhase 2Low Grade Ovarian Serous AdenocarcinomaOncologyDec 2026
NCT04439331defactinibPhase 2Advanced LymphomaOncologyJan 2027
NCT05787561avutometinibPhase 2Mesonephric Gynecologic CancerOncologyMar 2027
NCT05787561defactinibPhase 2Mesonephric Gynecologic CancerOncologyMar 2027
NCT05074810avutometinibPhase 1Non Small Cell Lung CancerOncologyApr 2027
NCT06394804avutometinibPhase 2Low-Grade Serous Ovarian CancerOncologyApr 2027
NCT05074810defactinibPhase 1Non Small Cell Lung CancerOncologyApr 2027
NCT06394804defactinibPhase 2Low-Grade Serous Ovarian CancerOncologyApr 2027
NCT04331041defactinibPhase 2Pancreas CancerOncologyApr 2027
NCT07659795VS-7375Phase 2Colorectal CancerOncologyJun 2027
NCT07659782VS-7375Phase 2Non-Small Cell Lung CancerOncologyJun 2027
NCT07644559VS-7375Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)OncologyJun 2027
NCT06007924avutometinibPhase 2Thyroid CancerOncologyAug 2027
NCT06007924defactinibPhase 2Thyroid CancerOncologyAug 2027
NCT05669482avutometinibPhase 1KRAS Activating MutationOncologyAug 2027
NCT05669482defactinibPhase 1KRAS Activating MutationOncologyAug 2027
NCT06682572avutometinibPhase 2Low Grade Serous Ovarian CancerOncologyOct 2027
NCT06682572defactinibPhase 2Low Grade Serous Ovarian CancerOncologyOct 2027
NCT05512208avutometinibPhase 2Endometrioid CancerOncologyDec 2027
NCT05512208defactinibPhase 2Endometrioid CancerOncologyDec 2027
NCT05636514defactinibPhase 1Myelodysplastic SyndromesOncologyDec 2027
NCT05608252avutometinibPhase 1Breast CancerOncologyDec 2027
NCT06194929avutometinibPhase 1Cutaneous MelanomaOncologyJan 2028
NCT06194929defactinibPhase 1Cutaneous MelanomaOncologyJan 2028
NCT07318324avutometinibPhase 1Phase IBOncologyAug 2028
NCT07318324defactinibPhase 1Phase IBOncologyAug 2028
NCT06072781avutometinibPhase 3Low Grade Serous Ovarian CancerOncologyOct 2028
NCT06072781defactinibPhase 3Low Grade Serous Ovarian CancerOncologyOct 2028
NCT06487221avutometinibPhase 2Gastric CancerOncologyNov 2028
NCT06487221defactinibPhase 2Gastric CancerOncologyNov 2028
NCT07020221VS-7375Phase 1Pancreatic Ductal AdenocarcinomaOncologyDec 2028
NCT06369259avutometinibPhase 2Advanced Colorectal CancerOncologyFeb 2029
NCT06369259defactinibPhase 2Advanced Colorectal CancerOncologyFeb 2029
NCT06495125avutometinibPhase 2Advanced Lung AdenocarcinomaOncologyMar 2029
NCT06495125defactinibPhase 2Advanced Lung AdenocarcinomaOncologyMar 2029
NCT06630260avutometinibPhase 1Glioblastoma Multiforme (GBM)OncologySep 2029
NCT06630260defactinibPhase 1Glioblastoma Multiforme (GBM)OncologySep 2029
NCT07126158avutometinibPhase 2Pancreatic AdenocarcinomaOncologyApr 2030
NCT07126158defactinibPhase 2Pancreatic AdenocarcinomaOncologyApr 2030

From the company's SEC filings

Cash and short-term investments of $173m on 2026-09-30; operating cash outflow about $174m a year; runway about 12 months at that burn, to Sep 2027; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

KRAS (1) MAP2K1 (1) MAP2K2 (1) PTK2 (1) PTK2B (1)

Companies with the same targets

Roche Revolution Medicines Novartis TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Quanta Therapeutics Pfizer Eli Lilly Chia Tai Tianqing Pharmaceutical Group Bristol-Myers Squibb Amgen

Companies built like this

Immuneering Aura Biosciences InxMed (Shanghai) UroGen Pharma Can-Fite BioPharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.